Adam Crystal - 01 Jul 2026 Form 4 Insider Report for Tango Therapeutics, Inc. (TNGX)

Reporting relationship: President, R&D
Issuer ticker: TNGX
Reported as of: 01 Jul 2026
Net transaction value: -$798,908
SEC form: 4
Accepted by SEC: 02 Jul 2026, 19:23:37 UTC
Prior SEC filing: 03 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Julie Fogarty, as attorney-in-fact

Key filing fact

Adam Crystal filed Form 4 for Tango Therapeutics, Inc. (TNGX) on 02 Jul 2026.

Key facts

This page summarizes Adam Crystal's Form 4 filing for Tango Therapeutics, Inc. (TNGX).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Jul 2026, 19:23.

Change

Previous filing in this sequence was filed on 03 Jun 2026.
Current net transaction value: -$798,908.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001825445 Primary reporting owner

Crystal Adam

Relationship: President, R&D
Address: C/O TANGO THERAPEUTICS, INC.,, 201 BROOKLINE AVE., SUITE 901, BOSTON
Signature: /s/ Julie Fogarty, as attorney-in-fact
Signature date: 02 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNGX transaction

Common Stock

Options Exercise

Transaction value
Shares: +27,000
Change %: +23%
Price: $5.20^*
Shares after: 142,743
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1

TNGX transaction

Common Stock

Sale

Transaction value: $575,962
Shares: -19,629
Change %: -14%
Price: $29.34
Shares after: 123,114
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F2

TNGX transaction

Common Stock

Sale

Transaction value: $222,946
Shares: -7,371
Change %: -6%
Price: $30.25
Shares after: 115,743
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNGX transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
Shares: -27,000
Change %: -7.9%
Price: $0.000000^*
Shares after: 314,040
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 27,000
Exercise price: $5.20
Footnotes: F1, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on October 27, 2025.

Footnote F2

Represents the weighted average sales price per share. The shares sold at prices ranging from $28.715 to $29.71 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F3

Represents the weighted average sales price per share. The shares sold at prices ranging from $29.72 to $30.65 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

Footnote F4

This option shall vest and become exercisable over a four-year period, at a rate of 25% on February 27, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter.